Breast Imaging Reporting and Data System v2025: Key Updates in MRI Authors: Jin You Kim Published: 2026 ABSTRACT AbstractThe American College of Radiology Breast Imaging Reporting and Data System (BI-RADS®) provides a standardized lexicon and reporting framework for breast MRI interpretation. The recently released BI-RADS® v2025 introduces refinements to breast MRI reporting, focusing primarily on clarification, standardization, and structural reorganization rather than fundamental changes to diagnostic principles. Key updates include more structured guidance on MRI acquisition and reporting; harmonization and removal of selected descriptors; incorporation of T2 signal intensity into mass characterization; reorganization of lymph node evaluation into a dedicated section; and clarification of associated features, such as peritumoral edema. Additionally, the updated Manual provides refined guidance for MRI assessment within a more structured clinical indication framework. This article provides an overview of the key updates introduced in BI-RADS® v2025 for breast MRI.Keywords: Breast, Magnetic Resonance Imaging, BI-RADS, Terminology INTRODUCTION Breast MRI plays an essential role in breast cancer detection because of its high sensitivity. It is widely used for screening high-risk populations, preoperative staging, and assessing treatment response (1). Despite its established clinical value, variability in MRI acquisition protocols and lesion characterization may limit interpretive consistency and reproducibility among radiologists. To address these challenges, the American College of Radiology (ACR) developed the Breast Imaging Reporting and Data System (BI-RADS®), which provides a standardized lexicon and reporting framework for breast MRI interpretation. Breast MRI was first incorporated into BI-RADS® in the fourth edition published in 2003 (2), and the lexicon was subsequently expanded in the fifth edition (3). The recently released BI-RADS® v2025 builds on the fifth edition and introduces refinements in acquisition parameters, descriptor definitions, reporting structure, and assessment guidance, based on accumulated clinical experience (4). This article reviews the key updates introduced in BI-RADS® v2025 for breast MRI and highlights the changes relevant to MRI interpretation. MRI ACQUISITION PARAMETERS IN BI-RADS® v2025 BI-RADS® v2025 outlines recommended acquisition principles to support reliable lesion detection and characterization in breast MRI. Although a single standardized protocol is not mandated, the Manual emphasizes key technical elements, including adequate spatial and temporal resolution, sufficient signal-to-noise ratio, an appropriate field of view, and bilateral breast coverage using dedicated breast coils. Dynamic contrast-enhanced MRI remains the foundation of contemporary breast MRI protocols. Early post-contrast imaging is typically performed approximately 60–120 seconds after contrast administration, corresponding to the phase during which many invasive cancers exhibit rapid enhancement. Consistency in protocol design is encouraged to facilitate comparison with prior examinations and to support reproducible interpretation. The updated Manual also addresses evolving imaging strategies. Abbreviated breast MRI protocols are shortened examinations designed to reduce scan time and improve accessibility. Although no single standardized protocol exists, most include a pre-contrast T1-weighted sequence and an early post-contrast acquisition; some protocols may also incorporate T2-weighted imaging. Total scan times are generally less than 10 minutes. Diffusion-weighted imaging (DWI) is included as a complementary non–contrast-enhanced technique; however, standardized reporting guidelines for DWI have not yet been incorporated into the BI-RADS® lexicon. The International Breast DWI Working Group classification may be applied, categorizing diffusion levels as very low, low, intermediate, high, and very high (5). Ultrafast dynamic contrast-enhanced MRI is introduced as an emerging technique that enables more detailed evaluation of very early enhancement kinetics. Other advanced techniques—including proton MR spectroscopy, sodium MRI, chemical exchange saturation transfer imaging, hypoxia imaging, and ultra-high-field-strength MRI—remain investigational within the current BI-RADS® framework. UPDATES TO THE BREAST MRI LEXICON IN BI-RADS® v2025 BREAST TISSUE COMPOSITION Breast tissue composition on MRI, including fibroglandular tissue (FGT) and background parenchymal enhancement (BPE), is summarized in Table 1. BI-RADS® v2025 retains the qualitative categorization of FGT (almost entirely fatty, scattered FGT, heterogeneous FGT, and extreme FGT) and BPE (minimal, mild, moderate, and marked). Notably, the definition of minimal BPE has been revised to explicitly include the absence of enhancement (Table 1). Table 1Changes in Breast Tissue CompositionTermsBreast Tissue2013 BI-RADS® Atlas (5th Edition)ACR BI-RADS® v2025ChangesAmount of fibroglandular tissuea. Almost entirely fattyb. Scattered fibroglandular tissuec. Heterogeneous fibroglandular tissued. Extreme fibroglandular tissueBackground parenchymal enhancementLevela. MinimalIncludes no enhancementb. Mildc. Moderated. MarkedSymmetrya. Symmetricb. AsymmetricACR = American College of Radiology, BI-RADS = Breast Imaging Reporting and Data System Changes in Breast Tissue Composition ACR = American College of Radiology, BI-RADS = Breast Imaging Reporting and Data System MASS AND NON-MASS ENHANCEMENT DESCRIPTORS Mass and non-mass enhancement (NME) represent the two principal categories of enhancing lesions on breast MRI. Updates to descriptors for these findings are summarized in Table 2. A key change in BI-RADS® v2025 is the removal of the term focus from the lexicon. In the fifth edition, focus referred to very small enhancing findings (3); however, these findings are frequently benign, and the term has been applied inconsistently in clinical practice and in the literature. In BI-RADS® v2025, small enhancing findings (≤5 mm) are instead classified according to morphologic criteria as either small masses or focal NME. This revision is intended to reduce ambiguity in lesion characterization and improve consistency in MRI interpretation. Table 2Changes in Breast Finding Description (Mass and Non-Mass Enhancement)TermsFindings2013 BI-RADS® Atlas (5th Edition)ACR BI-RADS® v2025ChangesFocusRemovedMass1. Shapea. Ovala. Ovalb. LobulatedAddedb. Roundc. Roundc. Irregulard. Irregular2. Margina. Circumscribeda. Circumscribedb. Not circumscribedb. Non-circumscribedTerminology revisioni. Irregulari. IndistinctIndistinct replaces irregularii. Spiculatedii. Spiculated3. Internal enhancement patterna. Homogeneousa. Homogeneousb. Dark internal septationsb. Dark internal septationsc. Heterogeneousc. Heterogeneousd. Rim enhancementd. Thick rim enhancementTerminology revision4. T2 signal intensitya. HyperintenseAddedb. Not hyperintenseNon-mass enhancement1. Distributiona. Diffusea. Diffuseb. Regionalb. Regionalc. Focalc. Focald. Lineard. Lineare. Segmentale. Segmentalf. Multiple regionsRemoved2. Internal enhancement patterna. Homogeneousb. Heterogeneousc. Clumpedd. Clustered ringACR = American College of Radiology, BI-RADS = Breast Imaging Reporting and Data System Changes in Breast Finding Description (Mass and Non-Mass Enhancement) ACR = American College of Radiology, BI-RADS = Breast Imaging Reporting and Data System For mass characterization, descriptors related to shape, margin, and internal enhancement pattern remain central (Figs. 1, 2). The shape descriptor lobulated, previously included within the oval category, is now defined as a distinct descriptor for describing masses with gentle contour undulations. For margins, the descriptor irregular has been replaced by indistinct to avoid overlap with shape descriptors and to harmonize MRI terminology with that used in mammography and ultrasound. The internal enhancement descriptor thick rim enhancement replaces the previous term rim enhancement, emphasizing its distinction from the thin pericystic enhancement observed in benign cysts (Fig. 3). T2 signal intensity is now included as a sub-finding in mass characterization and is categorized as hyperintense or not hyperintense (Fig. 4). Although both benign and malignant masses may appear hyperintense on T2-weighted images, a T2-hyperintense mass that is oval, circumscribed, and demonstrates homogeneous internal enhancement or dark internal septations is associated with a low probability of malignancy (≤2%) (6). Minor terminology revisions have also been introduced, including changing “not circumscribed” to “non-circumscribed.” Preoperative breast MRI in a 46-year-old woman with invasive ductal carcinoma of the left breast. A. Early post-contrast T1-weighted image shows an irregular enhancing mass with indistinct margins and heterogeneous internal enhancement in the left breast at the 3 o’clock position, corresponding to the known malignancy. B. Early post-contrast T1-weighted image shows a lobulated enhancing mass with circumscribed margins and dark internal septations in the left breast at the 4 o’clock position, confirmed as a fibroadenoma. Preoperative breast MRI in a 56-year-old woman with invasive ductal carcinoma of the right breast. A. Early post-contrast T1-weighted image shows an irregular enhancing mass with spiculated margins and heterogeneous internal enhancement in the right breast at the 10 o’clock position, corresponding to the known malignancy. B. Early post-contrast T1-weighted image shows a lobulated enhancing mass with circumscribed margins and homogeneous internal enhancement in the right breast at the 6 o’clock position, confirmed as a fibroadenoma. Preoperative breast MRI in a 59-year-old woman with invasive ductal carcinoma of the right breast. The early post-contrast subtraction image shows an irregular mass with indistinct margins and thick rim enhancement in the right breast at the 12 o’clock position, corresponding to the known malignancy. Breast MRI in a 44-year-old woman with biopsy-proven fibroadenoma. A. Post-contrast T1-weighted image shows an oval enhancing mass with circumscribed margins and heterogeneous internal enhancement in the left breast. B. Fat-suppressed T2-weighted image shows the lesion as hyperintense. T2 signal intensity is assessed subjectively, typically by comparison with a normal lymph node as an internal standard. For NME, descriptors remain largely unchanged in BI-RADS® v2025. However, the multiple regions distribution category has been removed, while other distribution and internal enhancement pattern descriptors are retained (Table 2). ENHANCEMENT KINETICS In BI-RADS® v2025, the term kinetic curve assessment has been refined to enhancement kinetics. Additionally, the term early post-contrast series replaces initial post-contrast series for images acquired approximately 60–120 seconds after contrast administration. This terminology update reflects the use of ultrafast MRI techniques, which may capture earlier phases of contrast enhancement before conventional dynamic series. Enhancement kinetics may aid in lesion characterization but should be interpreted in the context of morphologic features. LYMPH NODES In BI-RADS® v2025, lymph node evaluation is presented as a separate category rather than as an associated feature (Fig. 5, Table 3). This change reflects the increasing clinical importance of nodal assessment in staging and treatment planning. Breast MRI enables comprehensive evaluation of the axillae with a wide field of view, facilitating the detection of abnormal lymph nodes and bilateral comparison (7). The updated lexicon provides location-specific descriptors for intramammary, axillary, and internal mammary lymph nodes, each categorized as normal or abnormal. Currently, no validated quantitative size or cortical thickness thresholds exist for lymph node assessment on breast MRI. Accordingly, evaluation should rely primarily on morphologic features, comparison with prior or contralateral nodes, and clinical context. MRI of various lymph nodes. A, B. Normal intramammary lymph node. Fat-suppressed post-contrast T1-weighted (A) and T2-weighted (B) images show a normal left intramammary lymph node (arrows). The node demonstrates a well-circumscribed, reniform shape with a preserved fatty hilum and is hyperintense on T2-weighted imaging. C, D. Abnormal axillary lymph node. Fat-suppressed post-contrast T1-weighted images show multiple abnormal lymph nodes (arrows) at left axillary levels I and II. Level I nodes are located lateral to the pectoralis minor muscle, whereas level II nodes are located posterior to the pectoralis minor. E, F. Abnormal internal mammary lymph node. Fat-suppressed post-contrast T1-weighted images show invasive ductal carcinoma in the left breast with chest wall involvement (E) and an abnormal internal mammary lymph node (arrow) in the left second intercostal space (F). Table 3Changes in Lymph Node DescriptionTerms2013 BI-RADS® Atlas (5th Edition)ACR BI-RADS® v2025Associated featuresLymph nodesAxillary adenopathy1. Intramammarya. Normalb. Abnormal2. Axillarya. Normalb. Abnormal3. Internal mammarya. Normalb. AbnormalACR = American College of Radiology, BI-RADS = Breast Imaging Reporting and Data System Changes in Lymph Node Description ACR = American College of Radiology, BI-RADS = Breast Imaging Reporting and Data System ASSOCIATED FEATURES AND OTHER FINDINGS BI-RADS® v2025 introduces several terminology and structural changes to associated features and other MRI findings (Table 4). The term invasion has been replaced by involvement, and discussion of axillary adenopathy has been moved to a dedicated lymph node category. The descriptor architectural distortion has been removed from this section. Notably, peritumoral edema has been added as a new associated feature (Fig. 6), and is defined as T2-weighted hyperintensity in the breast parenchyma surrounding a malignant or suspicious lesion. This finding may suggest malignancy and has been associated with an increased risk of lymph node metastases in patients with extensive disease (8); however, it may also occur in benign conditions such as post-biopsy changes. Additionally, the previous category of non-enhancing findings has been revised as Other Findings—Typically Benign. The former subcategory of fat-containing lesions has been discontinued, with individual sub-findings redistributed to other sections of the lexicon. Table 4Changes in Breast Finding Description (Associated Features and Other Findings)Terms2013 BI-RADS® Atlas (5th Edition)ACR BI-RADS® v2025ChangesAssociated features1. Nipple retraction1. Nipple retraction2. Nipple invasion2. Nipple involvementInvasion changed to involvement3. Skin retraction3. Skin retraction4. Skin thickening4. Skin thickening5. Skin invasion (direct invasion/Inflammatory cancer)5. Skin involvementInvasion changed to involvement6. Axillary adenopathyRemoved7. Pectoralis muscle invasion6. Pectoralis muscle involvementInvasion changed to involvement8. Chest wall invasion7. Chest wall involvementInvasion changed to involvement8. Peritumoral edemaAdded9. Architectural distortionRemovedNon-enhancing findingsOther Findings—Typically Benign1. Ductal pre-contrast high signal on T1W1. High T1 duct signalTerminology revision2. Cyst2. Cysts3. Postoperative collections (hematoma/seroma)3. Postoperative fluid collections (hematoma/seroma)4. Post-therapy skin thickening and trabecular thickening4. Post-therapy skin thickening and trabecular thickening5. Non-enhancing mass5. Non-enhancing mass6. Architectural distortionRemoved7. Signal void from foreign bodies, clips, etc.6. Signal voidTerminology revision7. Fat necrosisRelocated8. HamartomaRelocated9. Enhancing skin lesionsFat containing lesionsDiscontinued1. Lymph nodes (normal/abnormal)2. Fat necrosis3. Hamartoma4. Postoperative seroma/hematoma with fatIntramammary lymph nodeRemovedSkin lesionRemovedACR = American College of Radiology, BI-RADS = Breast Imaging Reporting and Data System Changes in Breast Finding Description (Associated Features and Other Findings) ACR = American College of Radiology, BI-RADS = Breast Imaging Reporting and Data System Preoperative breast MRI in a 67-year-old woman with invasive ductal carcinoma of the right breast. A. Early post-contrast T1-weighted image shows an irregular enhancing mass with indistinct margins and heterogeneous internal enhancement, corresponding to the known malignancy. B. Fat-suppressed T2-weighted image shows hyperintense signal in the surrounding breast parenchyma (arrows), consistent with peritumoral edema. UPDATES TO THE REPORTING SYSTEM IN BI-RADS® v2025 BI-RADS® v2025 refines the breast MRI reporting system while retaining the established assessment categories (0-6). A single overall BI-RADS assessment category should be assigned per examination based on the highest-order actionable category, according to the BI-RADS assessment hierarchy (5 > 4 > 0 > 6 > 3 > 2/1). The use of BI-RADS Category 0 (incomplete) is clarified by distinguishing between cases that require additional imaging evaluation and those that require prior imaging for comparison. Category 0 should be used sparingly in breast MRI because examinations typically permit definitive assessment. For BI-RADS Category 3 (probably benign), the expected malignancy rate remains greater than 0% to ≤2%, with recommended short-interval follow-up at 6, 12, and 24 months. Caution is warranted when applying Category 3 to findings on non-baseline examinations, as higher malignancy rates have been reported compared with baseline studies (9). In examinations performed for extent-of-disease evaluation in patients with known breast cancer, Category 3 is generally discouraged; findings that might otherwise be considered probably benign may warrant classification as Category 4A. BI-RADS Category 4 (suspicious) includes findings with a broad range of malignancy probability (>2% to <95%). Optional subdivision of Category 4 (4A–4C) is now available for breast MRI, facilitating audit, supporting research, and improving understanding of the level of suspicion among clinicians and patients. BI-RADS Category 6 applies to biopsy-proven malignancy before definitive therapy. In BI-RADS® v2025, Category 6 may also be assigned to additional close findings (ACFs) that are suspicious but not definitively malignant (Fig. 7), provided that specific criteria are met: 1) the finding is within 2 cm of the biopsy-proven malignancy, 2) inclusion of the finding does not increase the total disease extent by more than 2 cm, and 3) the finding is not expected to alter clinical management. ACFs should be fully described, including their size and spatial relationship to the index malignancy; the term “satellite” should be avoided. Findings that do not meet ACF criteria should be assigned a separate BI-RADS assessment (Category 0, 4, or 5) based on imaging features. Preoperative breast MRI in an 84-year-old woman with invasive ductal carcinoma of the left breast. A. Early post-contrast T1-weighted image shows the index cancer in the upper outer quadrant of the left breast (BI-RADS Category 6). An additional finding (arrow) is located within 2 cm of the index lesion. Its inclusion does not increase the overall disease extent by more than 2 cm or alter clinical management. This finding meets the criteria for an ACF and may be assessed as Category 6 without a separate assessment. B. Computer-aided diagnosis–generated color-coded maximum intensity projection image demonstrates heterogeneous enhancement of the index lesion and the adjacent ACF. ACF = additional close finding, BI-RADS = Breast Imaging Reporting and Data System BI-RADS® v2025 also aligns breast MRI with a structured reporting framework used across other imaging modalities. Reports should include the clinical indication, prior comparison, acquisition parameters, FGT, BPE, key findings, assessment, and management recommendations. Notably, the level of BPE is explicitly incorporated into structured reporting elements. The framework also incorporates standardized clinical indication categories—asymptomatic screening, diagnostic work-up, and diagnostic: current breast cancer—emphasizing the importance of clinical context in image interpretation and enabling consistent outcome assessment. SUMMARY An accurate and standardized description of imaging findings is essential for effective communication in breast MRI interpretation. BI-RADS® v2025 introduces several refinements that reflect the evolution of MRI techniques and clinical practice. Key updates include revisions to selected lexicon descriptors, incorporation of T2 signal characteristics into mass assessment, reorganization of lymph node evaluation as a separate category, and the addition of new associated features such as peritumoral edema. Collectively, these changes enhance clarity, consistency, and reproducibility in breast MRI interpretation and reporting, thereby supporting informed clinical decision-making. Footnotes Conflicts of Interest: The author has no potential conflicts of interest to disclose. Funding: This work was supported by a clinical research grant from Pusan National University Hospital in 2022. The funders had no role in study design, data collection, and analysis, decision to publish, or preparation of the manuscript. Supplementary Materials Korean translation of this article is available with the Online-only Data Supplement at http://doi.org/10.3348/jksr.2026.0042. SUPPLEMENTARY MATERIAL References Associated Data Supplementary Materials SUPPLEMENTARY MATERIAL